Skip to main content

Zero layoffs across
two decades
of scale

From the founding team that scaled a 600-person biometrics CRO to a Summit Partners exit.

Flag data anomalies before database lock

Welcome to Acrosian

The Biometrics CRO
for the AI era.

Integrated data management, biostatistics, statistical programming, and medical writing — delivered by senior biometrics experts with two decades of CRO scale experience and a validated, audit-ready framework engineered from day one, with AI augmentation being progressively built into every function.

20 years. Building biometrics at scale

One of the industry’s largest independent biometrics CROs.
Operations spanning
three continents.
Successful exit
to private equity.
What We Do

Acrosian is a single integrated biometrics CRO partner bringing together the four functions that have the greatest impact on clinical trial timelines and submission quality:

01

Clinical Data Management

02

Biostatistics

03

Statistical Programming

04

Medical Writing

Every function is built on the same integrated delivery model, with AI augmentation being progressively added under a unified GxP validation framework.

One point of accountability.  
One quality system. One audit trail.

The AI Advantage

AI changes the ratio of senior judgment to repetitive labor.

AI does not replace the need for expert biometrics professionals. It changes the ratio of senior judgment to repetitive labor. A senior expert team, with AI augmentation being progressively built in, is positioned to deliver outcomes faster, more consistently, and with the validation rigor that regulatory submissions require.

These outcomes have traditionally demanded headcount-driven delivery.

We designed Acrosian around AI from day one. There is no legacy delivery model to retrofit. There is no organizational complexity to overcome. There is the work done by the people best equipped to do it in the era we are now in.

Why Now

Two decades ago, our founding team built a biometrics CRO on the leverage that the internet era made possible.

We scaled it into one of the industry’s largest independent biometrics CROs, with operations spanning three continents, and successfully exited to private equity.

We saw AI changing biometrics in fundamental ways, and we made a deliberate decision: rather than build on top of legacy systems designed for a different era, we chose to start fresh with an AI-augmented biometrics CRO built specifically for the future of clinical research. That restart is Acrosian.

Two decades ago

Built for the internet era

20 years of scale

One of the industry’s largest independent biometrics CROs

The exit

Successful exit
to private equity

Now

Started fresh
for the AI era